Aemetis’ (AMTX) “Sell (E+)” Rating Reiterated at Weiss Ratings

Weiss Ratings restated their sell (e+) rating on shares of Aemetis (NASDAQ:AMTX) in a research note issued to investors on Friday morning,Weiss Ratings reports.

A number of other research analysts have also recently weighed in on the stock. UBS Group lifted their price target on shares of Aemetis from $2.20 to $3.00 and gave the company a “buy” rating in a research report on Monday, June 30th. Ascendiant Capital Markets lifted their price target on shares of Aemetis from $20.00 to $21.00 and gave the company a “buy” rating in a research report on Monday, October 6th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Aemetis currently has a consensus rating of “Moderate Buy” and an average target price of $17.33.

Aemetis Stock Up 2.0%

Shares of AMTX stock opened at $2.57 on Friday. The stock has a market cap of $162.53 million, a price-to-earnings ratio of -1.59 and a beta of 1.68. Aemetis has a fifty-two week low of $1.22 and a fifty-two week high of $4.73. The firm’s 50 day moving average price is $2.53 and its two-hundred day moving average price is $2.28.

Aemetis (NASDAQ:AMTX) last announced its quarterly earnings results on Thursday, August 7th. The specialty chemicals company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The business had revenue of $52.24 million for the quarter, compared to analysts’ expectations of $78.68 million. On average, equities analysts forecast that Aemetis will post -2.07 EPS for the current fiscal year.

Insider Activity

In other news, Director Francis P. Barton sold 26,452 shares of Aemetis stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $2.53, for a total transaction of $66,923.56. Following the sale, the director owned 208,518 shares in the company, valued at $527,550.54. This trade represents a 11.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 15.90% of the stock is owned by corporate insiders.

Institutional Trading of Aemetis

A number of hedge funds and other institutional investors have recently made changes to their positions in AMTX. Jane Street Group LLC bought a new stake in shares of Aemetis in the second quarter worth $634,000. Qube Research & Technologies Ltd bought a new stake in shares of Aemetis in the second quarter worth $246,000. Goldman Sachs Group Inc. increased its stake in shares of Aemetis by 71.9% in the first quarter. Goldman Sachs Group Inc. now owns 218,404 shares of the specialty chemicals company’s stock worth $380,000 after buying an additional 91,367 shares during the last quarter. Nuveen LLC bought a new stake in shares of Aemetis in the first quarter worth $153,000. Finally, Russell Investments Group Ltd. increased its stake in shares of Aemetis by 412.9% in the second quarter. Russell Investments Group Ltd. now owns 80,754 shares of the specialty chemicals company’s stock worth $200,000 after buying an additional 65,010 shares during the last quarter. Institutional investors own 27.02% of the company’s stock.

About Aemetis

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.